Cement G received FDA authorization earlier in 2022, according to an Oct. 24 company news release. It addresses the site of infection with a single-stage surgical approach. A clinical study found Cerament G reduces the risk of bone infection to 4.3 to 5.5 percent compared to 13.3 percent with standard care.
Cerament G is the first FDA approved combination antibiotic-eluting bone graft. Dr. Conway is head of bone and joint infection at Sinai Hospital of Baltimore.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
